Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
21
02
2022
received:
19
01
2022
accepted:
10
04
2022
pubmed:
7
5
2022
medline:
15
6
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
Bulevirtide (BLV) blocks the uptake of the hepatitis D virus (HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally approved by the EMA but real-life data on BLV efficacy are limited. Patients were treated with BLV monotherapy. Patients who did not achieve further decreases in HDV-RNA after 24 weeks were offered PEG-IFN as an add-on therapy in a response-guided manner. Twenty-three patients (m: 10, f: 13; mean age: 47.9 years, cirrhosis: 16; median ALT: 71 IU/ml; median HDV-RNA: 2.1 × 10 Long-term BLV monotherapy is safe and effectively decreases HDV-RNA and ALT-even in patients with cirrhosis. The optimal duration of BLV treatment alone or in combination with PEG-IFN remains to be established. An algorithm for a response-guided BLV treatment approach is proposed.
Sections du résumé
BACKGROUND AND AIM
Bulevirtide (BLV) blocks the uptake of the hepatitis D virus (HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally approved by the EMA but real-life data on BLV efficacy are limited.
METHODS
Patients were treated with BLV monotherapy. Patients who did not achieve further decreases in HDV-RNA after 24 weeks were offered PEG-IFN as an add-on therapy in a response-guided manner.
RESULTS
Twenty-three patients (m: 10, f: 13; mean age: 47.9 years, cirrhosis: 16; median ALT: 71 IU/ml; median HDV-RNA: 2.1 × 10
CONCLUSION
Long-term BLV monotherapy is safe and effectively decreases HDV-RNA and ALT-even in patients with cirrhosis. The optimal duration of BLV treatment alone or in combination with PEG-IFN remains to be established. An algorithm for a response-guided BLV treatment approach is proposed.
Identifiants
pubmed: 35514008
doi: 10.1111/apt.16945
pmc: PMC9321570
doi:
Substances chimiques
Antiviral Agents
0
Interferon-alpha
0
Lipopeptides
0
RNA, Viral
0
bulevirtide
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
144-154Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
J Infect Dis. 2018 Mar 28;217(8):1184-1192
pubmed: 29425306
Liver Int. 2021 Jul;41(7):1509-1517
pubmed: 33999515
J Hepatol. 2022 Jul;77(1):254-255
pubmed: 35306059
Hepatology. 2020 Mar;71(3):1023-1036
pubmed: 31365764
Gastroenterology. 2004 Jun;126(7):1740-9
pubmed: 15188169
Gastroenterology. 2014 Apr;146(4):1070-83
pubmed: 24361467
J Hepatol. 2020 Sep;73(3):523-532
pubmed: 32335166
J Infect Dis. 2020 Apr 27;221(10):1677-1687
pubmed: 31778167
Liver Int. 2015 Feb;35(2):381-90
pubmed: 24953516
Aliment Pharmacol Ther. 2021 Aug;54(4):462-469
pubmed: 34181772
Gut. 2021 Sep;70(9):1782-1794
pubmed: 34103404
J Hepatol. 2019 Oct;71(4):834-839
pubmed: 31302176
J Vis Exp. 2020 Jun 18;(160):
pubmed: 32628153
Drugs. 2020 Oct;80(15):1601-1605
pubmed: 32926353
J Hepatol. 2021 Mar;74(3):686-699
pubmed: 33276031
United European Gastroenterol J. 2021 Dec;9(10):1119-1127
pubmed: 34873866
Clin Pharmacol Ther. 2012 Sep;92(3):332-9
pubmed: 22871997
J Hepatol. 2022 Apr;76(4):959-974
pubmed: 35120736
Lancet Infect Dis. 2019 Mar;19(3):275-286
pubmed: 30833068
Gut. 2022 Jul;71(7):1373-1385
pubmed: 34266968
J Hepatol. 2016 Oct;65(4):692-699
pubmed: 27242316
Antiviral Res. 2021 Jan;185:104995
pubmed: 33321155
Aliment Pharmacol Ther. 2022 Jul;56(1):144-154
pubmed: 35514008
Hepatology. 2021 Dec;74(6):3479-3485
pubmed: 34331781
J Clin Microbiol. 2005 May;43(5):2363-9
pubmed: 15872267
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2342-49.e1-2
pubmed: 26044319
Liver Int. 2020 Apr;40(4):894-904
pubmed: 31898387
JCI Insight. 2017 Mar 9;2(5):e90780
pubmed: 28289714
J Hepatol. 2016 Sep;65(3):490-8
pubmed: 27132170
Hepatology. 2022 Jun;75(6):1551-1565
pubmed: 34860418
Hepatology. 2008 Apr;47(4):1363-70
pubmed: 18366115
Liver Int. 2021 Nov;41(11):2733-2746
pubmed: 34525253
J Hepatol. 2022 Feb;76(2):464-469
pubmed: 34699951
J Hepatol. 2013 Aug;59(2):251-6
pubmed: 23528378
Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):463-9
pubmed: 23199505
Hepatology. 2018 Sep;68(3):1057-1069
pubmed: 29572910
J Hepatol. 2016 Apr;64(1 Suppl):S32-S40
pubmed: 27084034